Disclaimer: This article is for general informational purposes only and is not medical advice. It does not replace guidance from your doctor or healthcare team. The information reflects publicly available guidance as of November 9, 2026 and may change as new research becomes available.
If you take a GLP-1 medication, you may have seen headlines about a rare eye condition called NAION and a new FDA warning.
News like this can be unsettling, especially when you're already navigating a treatment journey. But headlines rarely tell the whole story.
On November 9, 2026, the FDA announced that medications in the GLP-1 class must carry updated warnings about a potential increased risk of NAION. The condition is rare, but it can cause permanent vision loss.
Here's what the FDA found, what other medical organizations are saying, and what remains unknown.
What is NAION?
NAION stands for non-arteritic anterior ischemic optic neuropathy. It occurs when blood flow to the front part of the optic nerve is reduced. The optic nerve carries visual information from your eye to your brain.
NAION can cause sudden, painless vision loss, usually in one eye. The vision loss can be permanent, and the condition's underlying cause is not completely understood [1].
NAION is not new, and it also occurs in people who have never taken a GLP-1 medication.
Eye specialists describe it as the most common cause of sudden optic nerve injury in adults over 50. Estimates suggest it affects approximately 2.3 to 10.2 people per 100,000 adults over 50 each year [4].
What did the FDA announce?
On November 9, 2026, the FDA issued a Drug Safety Communication identifying a potential increased risk of NAION associated with GLP-1 receptor agonists [1].
The agency is requiring manufacturers of all GLP-1 receptor agonist medications covered by its communication to add information about this risk to the Warnings and Precautions section of their official prescribing information.
The requirement covers medications including:
- Semaglutide (Ozempic, Wegovy, Rybelsus)
- Tirzepatide (Mounjaro, Zepbound), a dual GIP/GLP-1 receptor agonist
- Liraglutide (Victoza, Saxenda)
- Other medications listed in the FDA announcement
Tirzepatide acts on two hormone receptors rather than just GLP-1, but the FDA explicitly includes it in this labeling action [1].
The FDA reports that NAION cases have been reported with every GLP-1 receptor agonist currently marketed in the United States [1].
Much of the published research has focused on semaglutide, while the potential risk associated with other medications, including tirzepatide, is less understood.
The American Academy of Ophthalmology (AAO) and North American Neuro-Ophthalmology Society (NANOS) caution that, until more evidence is available, the possible risk should not be assumed to be specific to semaglutide [3].
What did the FDA actually find?
The FDA's investigation was prompted partly by a 2024 study published in JAMA Ophthalmology that found an association between semaglutide and NAION.
Although the agency identified limitations in that study, the findings warranted further investigation.
The FDA reviewed clinical trials, real-world patient data, published research, and animal studies.
Here's what it found.
Clinical trials
Across 126 randomized clinical trials involving 134,253 patients, the FDA identified 15 probable cases of NAION:
- 10 cases among people taking GLP-1 medications
- 5 cases among people receiving a placebo
- No cases among people receiving other non-GLP-1 glucose-lowering medications
The reported rates were:
- 6.4 cases per 100,000 person-years among GLP-1 users
- 3.8 cases per 100,000 person-years among those receiving comparison treatments
A person-year represents one person followed for one year.
Because few cases occurred in individual trials, the FDA pooled data across trials. AAO and NANOS also note that few trials reported NAION events at all, which limits what trial data alone can show [1, 3].
Real-world patient data
The FDA also examined records from adults with type 2 diabetes who started GLP-1 medications or other commonly prescribed diabetes treatments.
The findings were mixed.
Compared with patients taking SGLT-2 inhibitors, one class of diabetes medications, there was no statistically significant increase in NAION risk.
Compared with patients taking DPP-4 inhibitors, another class, an increased risk was observed [1].
AAO and NANOS note that much of the available research consists of retrospective observational studies, which have significant limitations, including potential confounding from differences between patient groups [3].
Published studies
The FDA also reviewed published observational studies. It found that methodologically rigorous studies generally reported an increased risk among GLP-1 users compared with people taking certain other diabetes medications [1].
Taken together, the evidence was enough for the FDA to require a new warning.
The important distinction: The FDA describes a potential increased risk, and its review of animal data did not identify how GLP-1 medications might contribute to NAION [1]. AAO and NANOS state that a causal relationship has not been established [3].
What are other medical organizations saying?
The FDA isn't the first regulator to examine this issue.
European Medicines Agency (EMA)
In June 2025, the EMA concluded that NAION should be classified as a very rare side effect of semaglutide, meaning it may affect up to 1 in 10,000 people taking the medication [2].
The EMA recommended updating product information for semaglutide medications, including Ozempic, Wegovy, and Rybelsus.
It also recommended stopping semaglutide if NAION is confirmed.
The EMA advised that patients who experience a sudden loss of vision or rapidly worsening eyesight during treatment contact their doctor without delay [2].
American Academy of Ophthalmology (AAO) and North American Neuro-Ophthalmology Society (NANOS)
These two professional organizations published a joint consensus statement examining the available evidence.
Their assessment was that some studies suggest a small increase in risk, while others have found no association. They describe the overall risk as low and state that causation has not been established [3].
The organizations also differ from the EMA on what should happen after a confirmed NAION diagnosis.
Rather than recommending automatic discontinuation, they favor individualized decisions between patients and their healthcare teams.
AAO and NANOS explain their reasoning: stopping GLP-1 treatment could pose significant health risks for some people, including those with obesity, diabetes that has been difficult to manage with other therapies, or cardiovascular conditions. NAION also remains rare.
They recommend weighing these considerations with each patient rather than applying the same decision to everyone [3].
What does the FDA recommend?
The FDA provides its own guidance on discontinuation.
It advises healthcare professionals to consider discontinuing a GLP-1 medication in patients who develop NAION, unless the benefits of treatment clearly outweigh the risk.
For patients who have experienced a NAION event, the FDA recommends discussing whether to continue or stop their medication with their healthcare professional [1].
These recommendations reflect different approaches to a serious but uncommon condition.
What is still unknown?
Quite a bit.
Researchers have not established exactly how GLP-1 medications might contribute to NAION.
The FDA's review of animal studies did not identify a biological mechanism that could explain a potential increased risk [1].
There is also another complication: several known risk factors for NAION overlap with conditions common among people prescribed GLP-1 medications.
These include diabetes, high blood pressure, sleep apnea, and kidney disease [1].
That makes it difficult to separate the possible effects of the medication from the effects of underlying health conditions [1].
Eye anatomy can also matter. Many people who develop NAION have what specialists call a disc at risk, meaning the optic nerve head is relatively small or crowded [3].
Researchers are continuing to investigate these questions, including whether the risk differs among individual GLP-1 medications [3].
What symptoms should you know about?
According to the FDA, symptoms of NAION may include [1]:
- Sudden, painless vision loss in one eye, sometimes noticed upon waking
- Blurred or missing areas of vision, including blind spots or tunnel vision
- Changes or distortion in how colors appear
- Reduced sharpness of central vision, including blurry or hazy spots
The FDA says people experiencing any of these symptoms should contact a healthcare professional right away [1].
AAO and NANOS state that people taking GLP-1 medications who experience sudden vision loss should undergo immediate evaluation by an ophthalmologist [3].
These symptoms can have several causes, including conditions that require urgent treatment. NAION cannot be diagnosed from symptoms alone. Diagnosis requires an appropriate eye examination [4].
What if you've already had NAION?
The FDA notes that people who have experienced NAION in one eye have an increased risk of developing it in the other eye [1].
AAO and NANOS state that existing studies have not evaluated people with a previous NAION diagnosis who are prescribed GLP-1 medications, so safety in this setting is unknown.
They also state that patients with a history of vision loss in one eye or a prior NAION diagnosis should be informed of the possible risk [3].
AAO and NANOS recommend individualized discussions between patients and their healthcare teams when considering whether to start, continue, or discontinue GLP-1 treatment [3].
What does this mean if you're taking a GLP-1?
The FDA describes NAION as rare, the EMA classifies it as a very rare side effect of semaglutide, and AAO and NANOS describe the overall risk as low [1, 2, 3].
At the same time, because NAION can cause permanent vision loss, regulators consider it serious enough to warrant a warning.
Your health history matters. So do the condition being treated, the medication you're taking, and any other risk factors you may have.
A headline, an online discussion, or even an article like this one cannot account for those individual circumstances.
If the announcement raises concerns, your prescriber can help you understand the potential risks alongside the established benefits of your treatment.
And if you notice a sudden change in your vision, the FDA's advice is to contact a healthcare professional right away [1].
Where Glo fits in
Glo can help explain medical news like this in everyday language and help you prepare questions for your healthcare provider.
Glo cannot evaluate vision symptoms, assess your personal risk, or recommend medication changes. Those decisions belong with your healthcare team.
The Bottom Line
On November 9, 2026, the FDA announced a requirement for new safety warnings on GLP-1 medications.
The FDA identifies a potential increased risk of NAION, but the condition remains rare. Important questions about its causes and the risks associated with individual medications remain unanswered.
The FDA, EMA, and AAO/NANOS all emphasize the seriousness of sudden vision loss and the importance of prompt medical evaluation.
For questions about your medication, your healthcare team is the appropriate source of individualized guidance.
As research continues, recommendations may evolve. The FDA's official communications and your medication's prescribing information remain important sources for updates.
[1] U.S. Food and Drug Administration. (November 9, 2026). FDA Requires Safety Labeling Changes for Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RAs) Due to Potential Increased Risk of Rare But Serious Eye Condition. Drug Safety Communication.
[2] European Medicines Agency. (June 6, 2025). Meeting Highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 2-5 June 2025: PRAC Concludes Eye Condition NAION Is a Very Rare Side Effect of Semaglutide Medicines.
[3] DeParis, S. W., Oke, I., Gaier, E. D., et al. (2026). Glucagon-Like Peptide-1 Receptor Agonists and the Risk of Non-Arteritic Anterior Ischemic Optic Neuropathy: A Consensus Statement by the North American Neuro-Ophthalmology Society and the American Academy of Ophthalmology. Ophthalmology.
Read joint consensus statement
[4] Wu, K. Y., & Evoy, F. (August 2022). NAION: Diagnosis and Management. American Academy of Ophthalmology, EyeNet Magazine.
Category